Reference

Interactions of some cholinolytic anti-Parkinson drugs with nicotine and oxotremorine on rat diaphragm

Interactions of some cholinolytic anti-Parkinson drugs with nicotine and oxotremorine on rat diaphragm.Some chemicals with cas registry numbers like 65-30-5 and 1235-82-1 are also used. Das, Minati; Ganguly, D. K. (Div. Pharmacol., Indian Inst. Exp. Med., Calcutta, India). Toxicol. Appl. Pharmacol., 39(1), 149-52 (English) 1977. CODEN: TXAPA9. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Interactions between the cholinolytic anti-Parkinson drugs cycrimine-HCl [126-02-3], benztropine mesylate [132-17-2], and biperiden-HCl [1235-82-1], and the tremorogenic agents oxotremorine sesquifumarate [17360-35-9] and nicotine sulfate [65-30-5] were examd. employing isolated phrenic nerve-diaphragm prepns. in rats. Preincubation with the anti-Parkinson drugs prevented the impairment of neuromuscular transmission caused by oxotremorine and nicotine. The results indicate that the skeletal myoneural site may play a role in chem. induced Parkinson-like features in exptl. animals, as well as in its prevention by the anti-Parkinson drugs. .